Medical Condition News

RSS

Concerns over safety and effectiveness of "natural" treatments for treating anxiety

In a broad-based review of studies focused on drugs that treat anxiety, a Saint Louis University doctor found no evidence supporting the use of so-called "natural" treatments in combating the effects of anxiety.

7 Apr 2010

Non-conscious, learning systems of the brain simpler and evolutionarily older, study substantiates

A new study from the Swedish medical university Karolinska Institutet provides evidence that basic human learning systems use areas of the brain that also exist in the most primitive vertebrates, such as certain fish, reptiles and amphibians. The study involved an investigation into the limbic striatum, one of the evolutionarily oldest parts of the brain, and the ability to learn movements, consciously and unconsciously, through repetition.

7 Apr 2010

Researchers find small inverse relationship between intake of fruits, vegetables and cancer risk

An analysis by Mount Sinai researchers of over eight years of dietary data from more than 400,000 people has found that the relationship between high consumption of fruits and vegetables and a reduced risk of cancer is not as strong as commonly thought. The study is published online April 6, 2010 in the Journal of the National Cancer Institute.

7 Apr 2010

HOLCOMB C3-R cures bobsledder of impending blindness, helps win gold at 2010 Winter Olympics

It was an amazing triumph of the will, when the U.S. Bobsled Team, led by captain Steve Holcomb, took home the first Gold in 62 years at the 2010 Winter Olympics in Vancouver. An amazing feat, yet only the tip of the iceberg, for 2 years prior Holcomb underwent a brand new procedure to cure his impending blindness.

7 Apr 2010

New seminar series "Physical Care of Duchenne" unveiled

Duchenne Therapy Network today unveiled a new seminar series called, "Physical Care of Duchenne." The course, which includes two separate sessions taught by Jennifer Wallace, PT, will be held at the Ayres Hotel in Costa Mesa.

7 Apr 2010

Researchers commence Phase 2 research study to test CERE-110 for AD

Researchers at Banner Sun Health Research Institute are about to start the first Phase 2 research study to test a gene transfer agent for Alzheimer's disease. AD is a degenerative and ultimately fatal disorder affecting as many as five million Americans and that number is expected to soar to more than 11 million by 2040.

7 Apr 2010

Study provides benchmark data to evaluate quality of management of sickle cell disease

The largest study to date of the use of acute care medical services by people with sickle cell disease found four of every 10 had to return to the hospital within 30 days of a previous hospitalization or go to the emergency department for treatment of pain, according to a new study funded in part by HHS' Agency for Healthcare Research and Quality.

7 Apr 2010

Measure of blood flow in lungs could help identify smokers at risk of emphysema

Using CT scans to measure blood flow in the lungs of people who smoke may offer a way to identify which smokers are most at risk of emphysema before the disease damages and eventually destroys areas of the lungs, according to a University of Iowa study.

7 Apr 2010

Research highlights first steps in the formation of Lewy bodies, the hallmark of Parkinson's brain

Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein. The research, published by Cell Press online on April 6th in Biophysical Journal, provides new insight into the first steps in the formation of neurotoxic structures called Lewy bodies that are the hallmark of the Parkinson's brain.

7 Apr 2010

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., has jointly awarded a two-year, $200,000 grant to Dr. Joel Chamberlain, a research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool for facioscapulohumeral muscular dystrophy.

7 Apr 2010

Semel Institute for Neuroscience and Human Behavior awarded $14.9M to establish IPCN facility

The Semel Institute for Neuroscience and Human Behavior at UCLA has been awarded $14.9 million in American Recovery and Reinvestment Act funds to establish a center dedicated to interdisciplinary research on the role of genetic and environmental factors in neuropsychiatric and behavioral disorders.

7 Apr 2010

ESC heart failure meeting encourages audience interaction

"Delegates attending the meeting will get real insights into what's new in heart failure," said Professor Stefan Anker, chairman of the Heart Failure Congress Scientific Committee. "In what's the biggest international stand-alone meeting dedicated to heart failure, there'll be lots of hot of the press news. The very fact that 12 late breaking clinical trial updates are being presented at the meeting demonstrates how bright the future is in heart failure."

7 Apr 2010

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.

7 Apr 2010

Nationwide Phase III clinical trial of OncoVEX for advanced melanoma

Rush University Medical Center is leading a nationwide Phase III clinical trial to determine whether a promising vaccine for advanced melanoma can effectively treat the deadly skin cancer.

7 Apr 2010

Rome Foundation develops Diagnostic Algorithms to diagnose GI symptoms

New clinical algorithms will give physicians a practical, efficient and cost-effective aid to diagnose the frequent gastrointestinal symptoms that patients commonly bring to their primary care doctors and gastroenterologists--symptoms of functional GI disorders that are often difficult to diagnose.

7 Apr 2010

LCA: Few possess genetic mutation necessary for positive outcome from gene therapy

Leber congenital amaurosis (LCA) is a congenital retinal dystrophy present in approximately 1 of 80,000 births. It is estimated that about 3,000 people in the United States are living with LCA and will likely become blind in their lifetimes. Recently, there has been progress in gene therapy for this condition.

7 Apr 2010

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.

7 Apr 2010

Patients with sickle cell disease require acute care: Study

Patients with sickle cell disease average about 2.5 hospital visits per year, with 18- to 30-year old patients more likely to require acute care or rehospitalization, according to a study in the April 7 issue of JAMA.

7 Apr 2010

Blocking POLQ gene activity can increase ability of radiotherapy to destroy tumours

Cancer Research UK scientists have identified a gene that once blocked could increase the effectiveness of radiotherapy on tumours, according to research published in Cancer Research today (Thursday).

7 Apr 2010

MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL), in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. The trial, led by Shaji Kumar, MD, of Mayo Clinic, is open for enrollment at Mayo Clinic (Rochester, Minn.), City of Hope Cancer Center (Duarte, Calif.) and the University of Chicago (Chicago, Ill).

7 Apr 2010

Medical Condition News

Concerns over safety and effectiveness of "natural" treatments for treating anxiety

Non-conscious, learning systems of the brain simpler and evolutionarily older, study substantiates

Researchers find small inverse relationship between intake of fruits, vegetables and cancer risk

HOLCOMB C3-R cures bobsledder of impending blindness, helps win gold at 2010 Winter Olympics

New seminar series "Physical Care of Duchenne" unveiled

Researchers commence Phase 2 research study to test CERE-110 for AD

Study provides benchmark data to evaluate quality of management of sickle cell disease

Measure of blood flow in lungs could help identify smokers at risk of emphysema

Research highlights first steps in the formation of Lewy bodies, the hallmark of Parkinson's brain

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

Semel Institute for Neuroscience and Human Behavior awarded $14.9M to establish IPCN facility

ESC heart failure meeting encourages audience interaction

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Nationwide Phase III clinical trial of OncoVEX for advanced melanoma

Rome Foundation develops Diagnostic Algorithms to diagnose GI symptoms

LCA: Few possess genetic mutation necessary for positive outcome from gene therapy

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

Patients with sickle cell disease require acute care: Study

Blocking POLQ gene activity can increase ability of radiotherapy to destroy tumours

MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Latest News